These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 7191278)

  • 21. [Lowering lipids rapidly and permanently with etofibrate].
    von Bock und Polach U
    Med Klin; 1982 Jan; 77(3):35-8. PubMed ID: 7057729
    [No Abstract]   [Full Text] [Related]  

  • 22. [Chemistry of phenoxyacetic acid esters of oxyalkyltheophyllines and 1-(theophyllin-7-yl)-ethyl-2-[2-(p-chlorophenoxy)-2-methyl-propionate] (etofylline clofibrate), a novel antilipaemic agent (author's transl)].
    Metz G; Specker M
    Arzneimittelforschung; 1980; 30(11b):2014-9. PubMed ID: 7194051
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Hypolipemic effect of amino acid derivatives of clofibric acid].
    Wójcicki J; Samochowiec L; Gawrońska-Szklarz B; Kwapiszewski W; Borkowski L
    Acta Pol Pharm; 1985; 42(3):305-8. PubMed ID: 4096253
    [No Abstract]   [Full Text] [Related]  

  • 24. [An alternative in the therapy of primary hyperlipemias: etofibrate in depot preparations].
    Füsgen I; Summa JD
    Med Klin; 1980 Nov; 75(23):823-5. PubMed ID: 7442597
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasmolysis, red blood cell partitioning, and plasma protein binding of etofibrate, clofibrate, and their degradation products.
    Altmayer P; Garrett ER
    J Pharm Sci; 1983 Nov; 72(11):1309-18. PubMed ID: 6644594
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Etofibrate lowers the atherosclerosis index].
    Mertz DP; Suermann I; Göhmann E
    Med Klin; 1981 Mar; 76(6):166-8. PubMed ID: 7231329
    [No Abstract]   [Full Text] [Related]  

  • 27. Different behavior toward racemization in basic media from chiral analogs of clofibric acid, the active metabolite of the antilipidemic drug clofibrate.
    Ferorelli S; Loiodice F; Longo A; Molfetta A; Tortorella V; Amoroso R
    Chirality; 2000 Nov; 12(10):697-704. PubMed ID: 11054827
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hypolipemic activity of plafibride.
    Bruseghini L; Vilageliu J; Bagaria A
    Arzneimittelforschung; 1981; 31(10a):1796-800. PubMed ID: 7198456
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [What is important in therapy of hyperlipoproteinemia. Lipo-Merz retard (etofibrate) lowers the atherogenic index].
    Fortschr Med; 1982 Sep; 100(35):1622-3. PubMed ID: 7173769
    [No Abstract]   [Full Text] [Related]  

  • 30. Biopharmaceutic evaluation of etofylline clofibrate and its drug formulation.
    Ritschel WA; Thompson GA; Lücker PW; Wetzelsberger K
    Arzneimittelforschung; 1980; 30(11b):2020-3. PubMed ID: 7194052
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Plafibride--is it an effective drug as a hypolipemic agent?].
    Joven J
    Med Clin (Barc); 1985 Apr; 84(15):632. PubMed ID: 3999857
    [No Abstract]   [Full Text] [Related]  

  • 32. Plafibride tolerance trial at increasing doses in healthy volunteers.
    Dalmau J; Vicens B; Zapatero J; Bruseghini L
    Arzneimittelforschung; 1981; 31(10a):1840-4. PubMed ID: 7198462
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical trials of plafibride in geriatric patients.
    Demichelis Genesio MA; Bracons R; Vicens B; Zapatero J; Bruseghini L
    Arzneimittelforschung; 1981; 31(10a):1852-5. PubMed ID: 7198465
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of the hypolipaemic activity of etofylline clofibrate, a new ester of etofylline and clofibric acid, and comparison with effects of known hypolipaemic agents.
    Davies JE; Kellett DN
    Arzneimittelforschung; 1980; 30(11b):2035-7. PubMed ID: 7194055
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plafibride tolerance trial in healthy volunteers.
    Dalmau J; Vicens B; Zapatero J; Bruseghini L
    Arzneimittelforschung; 1981; 31(10a):1845-9. PubMed ID: 7198463
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diisopropylfluorophosphate increases clofibric acid clearance: supporting evidence for a futile cycle.
    Rowe BJ; Meffin PJ
    J Pharmacol Exp Ther; 1984 Jul; 230(1):237-41. PubMed ID: 6747828
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [On the uricosuric activity of etofylline clofibrate (author's transl)].
    Ziegler WJ
    Arzneimittelforschung; 1980; 30(11b):2073-4. PubMed ID: 7194063
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Toxic myopathy due to hypolipemic agents].
    Bourrier P; Subra JF; Chennebault JM; Spiesser R; Laine P
    Therapie; 1990; 45(4):360. PubMed ID: 2399525
    [No Abstract]   [Full Text] [Related]  

  • 39. [Use of etofibrate in the treatment of patients with hyperlipidemia and arteriosclerosis obliterans of the legs].
    Dembińska-Kieć A; Kostka-Trabka E; Grodzińska L; Bieroń K; Kedzior A; Basista M; Zmuda A; Trabka E; Sławiński M; Czarnecka B
    Pol Tyg Lek; 1987 Dec 21-28; 42(51-52):1643-8. PubMed ID: 3330798
    [No Abstract]   [Full Text] [Related]  

  • 40. [Therapy of vascular insufficiency of the legs with plafibride].
    Lázaro Campillo T; Gesto Castromil R; de la Sierra L; Pujadas J; Villafana W; Moreno R
    Med Clin (Barc); 1984 Dec; 83(18):752-5. PubMed ID: 6521538
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.